Jane Barry
Overview
Explore the profile of Jane Barry including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
109
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Buch M, Walker D, Edwards C, Barry J, Akroyd L, Ekoka Omoruyi E, et al.
Rheumatology (Oxford)
. 2024 Sep;
PMID: 39331638
Objectives: Clinical trials restricted to moderately active RA are limited. Filgotinib is approved for treating moderate to severe active RA. This post hoc analysis assessed efficacy and safety of filgotinib...
2.
OConnell M, Barry J, Hartigan I, Cornally N, Saab M
J Clin Nurs
. 2024 Mar;
33(7):2374-2387.
PMID: 38481071
Aim: To synthesise evidence from studies that explored the impact of electronic and self-rostering systems to schedule staff on healthcare organisations and healthcare workers. Design: Mixed-method systematic review. Methods: Studies...
3.
Walker D, Barry J, Akroyd L, Robinson S
Musculoskeletal Care
. 2023 Apr;
21(3):943-946.
PMID: 37095573
No abstract available.
4.
Winthrop K, Isaacs J, Calabrese L, Mittal D, Desai S, Barry J, et al.
Semin Arthritis Rheum
. 2022 Nov;
58:152120.
PMID: 36347212
Background: The availability of Janus kinase (JAK) inhibitors has transformed the management of rheumatoid arthritis (RA), helping patients achieve clinical remission. However, the emergence of opportunistic infections (OIs) associated with...
5.
Scott I, Mount J, Barry J, Kirkham B
BMC Rheumatol
. 2020 Oct;
4:63.
PMID: 33094270
Background: Many patients with rheumatoid arthritis (RA) do not attain remission/low disease activity, remaining in a moderate disease activity state (MDAS) with ongoing disability and impaired quality of life (QoL)....
6.
Edwards C, Kiely P, Arthanari S, Kiri S, Mount J, Barry J, et al.
Rheumatol Adv Pract
. 2019 Aug;
3(1):rkz002.
PMID: 31431990
Objectives: Access to biologic DMARDs for RA is often restricted to those with severe disease. This systematic review aimed to identify prognostic factors in patients with moderate disease activity who...
7.
Fautrel B, Alten R, Kirkham B, de la Torre I, Durand F, Barry J, et al.
Rheumatol Int
. 2018 Mar;
38(6):935-947.
PMID: 29564549
Current guidelines for the management of rheumatoid arthritis (RA) recommend early treatment and a treat-to-target goal of remission or low disease activity. Over the past decade, this approach has been...
8.
Brock G, Ni X, Oelke M, Mulhall J, Rosenberg M, Seftel A, et al.
J Sex Med
. 2016 Apr;
13(5):860-75.
PMID: 27114197
Introduction: Various factors play a role in the development of erectile dysfunction (ED). Aim: To provide a descriptive comparison of erectile function response for tadalafil on-demand (PRN) and once-daily (OAD)...
9.
Patel H, Ilo D, Shah N, Cuzin B, Chadwick D, Andrianne R, et al.
BMC Urol
. 2015 Apr;
15:31.
PMID: 25879460
Background: This multicenter, randomized, double-blind, double-dummy, placebo-controlled trial primarily evaluated the efficacy of tadalafil once-daily (OaD) or on-demand ("pro-re-nata"; PRN) treatment, started early post-nsRP. Secondary outcome-measures on quality-of-life (QoL) and...
10.
Pereira P, Barry J, Corkeron M, Keir P, Little M, Seymour J
Clin Toxicol (Phila)
. 2010 May;
48(4):390-2.
PMID: 20507250
Introduction: Irukandji syndrome is because of envenoming by a number of small jellyfish. It results in a delayed onset of generalized pain, sweating hypertension, and tachycardia. There is no antivenom....